Thermo Fisher's NSCLC Companion Dx Covered by Regence BCBS

Oct 16, 2017

UPDATE: The story had incorrectly stated that the test was FDA approved as a companion diagnostic to identify patients with ALK mutations who may respond to the cancer drug Xalkori. We regret the error.

NEW YORK (GenomeWeb) – Thermo Fisher Scientific today said its Oncomine Dx Target Test has received a positive coverage decision from Regence Blue Cross Blue Shield.

As a result, the insurer will cover the test for its members with non-small cell lung cancer in Oregon, Idaho, Utah, and certain counties in Washington.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

The BD Veritor Plus System

Advancing Patient Care and Aiding Diagnosis at the Point of Care

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Immuno-Oncology: 3 Strategies for Applying Humanized Models

Mar

26

Featured Webinar

Advancing Agricultural Genomics with Low-Cost NGS Genotyping

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Mar

28

Featured Webinar

The Human Gene Mutation Database: Empowering a Generation of Geneticists for Precision Medicine

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.

Apr

11

Featured Webinar

The 'Dark Matter' of Cancer Genomics: Revealing Undetected Structural Variants in Leukemia

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Menu